Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,496.00-0.54%ETH$2,695.79-0.76%GOLD$4,194.70+0.18%OIL$89.85+0.46%
Smart Investors Daily
SID Premium
CE

NASDAQ · CELC

Celcuity Inc.

Healthcare · Biotechnology

$73.62

Down-$2.37 (-3.22%)

Updated Oct 6, 2026, 9:56 PM

SID Score

4.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.66B
P/E ratio
-27.72
Dividend yield
0.00%
52-week range
$45.03 – $151.02
Volume
1.72M
Avg. volume
1.12M

Price performance · CELC

CELC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

CELC closed at $73.62 after 20 trading sessions, down 20.86% for the selected period.

Last close
$73.62
Period change
-20.86%
Period low
$72.10
Period high
$93.02
Daily close
View OHLC price history
CELC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$72.71$74.60$69.00$73.621.72M
Oct 2, 2026$75.21$75.44$70.675$72.101.42M
Oct 1, 2026$78.38$79.18$75.00$75.131.1M
Sep 30, 2026$81.30$88.68$77.84$79.522.56M
Sep 29, 2026$79.64$80.52$77.25$77.381.22M
Sep 28, 2026$79.44$80.02$77.09$79.64610.35K
Sep 25, 2026$80.00$80.2834$78.02$79.52657.17K
Sep 24, 2026$79.73$80.19$77.07$79.371.24M
Sep 23, 2026$84.93$85.05$79.40$79.99739.44K
Sep 22, 2026$84.00$85.50$82.80$84.10540.31K
Sep 21, 2026$81.37$84.33$80.26$84.00718.13K
Sep 18, 2026$84.89$85.1723$79.77$80.611.41M
Sep 17, 2026$85.22$87.50$84.41$84.91692.11K
Sep 16, 2026$83.33$84.07$81.5401$82.58799.31K
Sep 15, 2026$83.65$83.65$80.62$82.70783.66K
Sep 14, 2026$83.45$84.905$82.49$83.531.65M
Sep 11, 2026$86.38$87.01$83.235$83.45863.37K
Sep 10, 2026$88.37$89.475$84.82$85.491.07M
Sep 9, 2026$92.00$93.80$90.00$90.08708.29K
Sep 8, 2026$93.62$97.43$92.61$93.02941.04K

Latest CELC news

The latest Smart Investors Daily articles mentioning CELC.

Stock researchCompany · Overview

CELC research

Overview

Company profile and research snapshot.

Company profile

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$86.00
Implied upside
—
Analysts
—
CELC recent ratings
DateFirmRatingTarget
Sep 30, 2026NeedhamBuy—
Sep 17, 2026JP MorganOverweight—
Aug 17, 2026CitizensMarket Outperform—
Aug 17, 2026GuggenheimBuy—
Aug 14, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 3, 2026

Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?

Celcuity (CELC) has moved into a new phase, with REVTORPYK now commercially available in the US for certain advanced breast cancer patients, paired with a support program that targets access, affordability, and treatment logistics. Despite REVTORPYK’s US launch and the recent appointment of seasoned finance leader David W. Gryska to Celcuity’s board, the share price has pulled back, with the 30 day share price return down 25.1% and the 1 year total shareholder return still up 42.7%. This...

Yahoo · Oct 2, 2026

Celcuity Appoints David Gryska To Its Board Of Directors

Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s BoardMINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced the appointment of David W. Gryska to its Board of Directors. Mr. Gryska is a seasoned executive who brings over 35 years of strategic and financial leadership experience in

Yahoo · Sep 30, 2026

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

REVTORPYK (gedatolisib) REVTORPYK (gedatolisib) vial and box REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic settingREVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to comprehensively blockade the PI3K/AKT/mTOR (“PAM”) pathwayIn the PIK3CA wild-type coho

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By